Ixazomib citrate is the citrate form of ixazomib which is an inhibitor of chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 of 3.4 nM.

TH-263 is an inactive analog control for LIMK inhibitors TH-257, TH-255 and TH-251.

Thrombin inhibitor 5是一种选择性的凝血酶抑制剂，能有效阻断凝血酶的活性，从而干预血液凝固过程，对于血栓相关疾病的研究和治疗具有重要应用价值。

TCH-165 是蛋白酶体组装的小分子调节剂，可增加 20S 水平并促进 20S 介导的蛋白质降解。

Acetylcorynoline, a natural product isolated and purified from the tubers of Corydalis ambigua, has antifungal and anti-inflammatory activity.

BC-23 (NSC 45382) 是一种蛋白酶体抑制剂。它对蛋白酶体的 CT-L 活性表现出强效抑制，并对恶性细胞相比正常细胞具有更高的选择性。

3-Feruloylquinic acid是一种奎宁酸结合酚酸的衍生物，具有显著的抗氧化活性。该化合物在高光合作用有效辐射 (PAR) 和紫外线辐照下能够增强植物的抗氧化能力，适用于植物光合作用及抗氧化机制的研究。

Ixazomib（MLN2238）是一种选择性、强效和可逆的蛋白酶体抑制剂，靶向20S蛋白酶体的胰凝乳蛋白酶样蛋白水解（β5）位点，IC50为3.4 nM，Ki为0.93 nM。

AM 114 is an inhibitor of the chymotrypsin-like activity of the 20S proteasome with IC50 ~ 1 μM.

Fulacimstat 是一种口服可利用的胰凝乳蛋白酶抑制剂，对人和仓鼠胰凝乳蛋白酶的 IC50 值分别为 4 nM 和 3 nM。

Carfilzomib（PR-171）表现出对蛋白酶体的不可逆抑制作用，在ANBL-6和RPMI 8226细胞中的IC50为5 nM。

MG-115 是一种有效且可逆的蛋白酶体抑制剂，对 20S 和 26S 蛋白酶体的 Ki 值分别为 21 nM 和 35 nM。MG-115 特异性抑制蛋白酶体的胰凝乳蛋白酶样活性，诱导 p53 依赖的细胞凋亡。

VR23 is a small molecule inhibitor which targets β2 of the 20S proteasome with IC50 of 1 nM and can induce apoptosis of cancer cells via cyclin E–mediated centrosome amplification.

(1S,2S)-Bortezomib是 Bortezomib 的对映异构体，Bortezomib 是一种细胞渗透性、可逆性和选择性的蛋白酶体抑制剂，通过靶向苏氨酸残基抑制 20S 蛋白酶体，并诱导细胞凋亡，是第一个用于人类的蛋白酶体抑制剂，具有抗癌作用。

TY-51469 是一种胰凝乳蛋白酶抑制剂，对猿和人的胰凝乳蛋白酶的 IC50 分别为 0.4 和 7.0 nM。

ONX-0914 (PR-957) 是一种选择性免疫蛋白酶体的胰凝乳蛋白酶样亚基低分子质量多肽-7 (LMP7) 抑制剂。它通过 p-TEFb 激活介导的 HSF-1 激活阻断细胞因子生产并减少实验性关节炎的进展。ONX-0914 是一种不可逆的非竞争性抑制剂 (Ki = 5.2 μM) 并通过 p-TEFb 激活介导的 HSF-1 激活再活化潜伏的 HIV-1。

ONX 0912 is an inhibitor of proteasome that targets the chymotrypsin-like activity of the 20S proteasome subunits β5 (IC50 = 36 nM) and LMP7 (IC50 = 82 nM).

PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. It inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites, with anticancer activity.

(R)-MG132 can act as an inhibitor of proteasome and be used in ubiquitination assay.

RA190 is a potent Rpn13 inhibitor and ADRM1 Inhibitor, Suppressing Intrahepatic Cholangiocarcinoma by Inducing NF-kappaB-Mediated Cell Apoptosis. RA190 represents a novel class of proteasome inhibitor that covalently binds to cysteine 88 of RPN13, an ubiquitin receptor subunit of the proteasome's 19S regulatory particle. RA190 treatment inhibits proteasome function, causing rapid accumulation of polyubiquitinated proteins. RA190 has therapeutic activity in a xenograft model, and with sorafenib exhibited synergetic killing of HCC cells in vitro, suggesting further exploration of such a combination treatment of HCC is warranted.